No abstract

The coronavirus disease 2019 (COVID-19) pandemic is an astonishing universal situation and all countries have adopted their own strategies to eradicate the corona virus transmission. All measures are followed according to the World Health Organization recommendations. As it is a new infection, scientific data are limited, although progressing relentlessly. The infectivity and mortality are higher than other pandemics and the propagation has fluctuated extensively by location. Coronavirus belonging to the family Coronaviridae (CoV) cause acute respiratory syndrome and infect unciliated bronchial epithelial cells and pneumonocytes Type II, predominantly harbored in mammals. It has become imperative to make out the ability of virus in COVID-19 era that how it affects the reproductive capacity in humans and whether pregnant women are at higher risk of fatality or comorbidity. In this article, the possible outcomes of COVID-19 in relation to reproduction and fertility with emphasis on impact on contraceptive assess, risk on pregnancy, fetal health, and regulation of assisted reproduction have been reviewed.

Background: Reversible inhibition of sperm under guidance (“RISUG®”) is a promising intravasal male contraceptive. Objective: An exploratory study was conducted with a concept of non-invasive, transcervical, single-intervention and reversible contraception using RISUG® in females. Materials and Methods: In this experimental study, 60 adult Wistar albino female rats weighing 150-155 g, 3-4 months old were divided into four groups: group I: sham-operated control; group II: tubal occlusion with RISUG for 90 days; group III: tubal occlusion with RISUG® for 90 days and reversal with dimethyl sulphoxide and group IV: tubal occlusion with RISUG® for 90 days and reversal with 5% NaHCO3. Animals were subjected to bilateral fallopian tube occlusion with RISUG® and reversal with DMSO and NaHCO3. The estrous cycle, fertility and histology of fallopian tube were evaluated. Results: Group I showed 100% fertility during all mating schedules. Animals of experimental groups indicated positive mating, but 0% fertility was evident following 30, 60, and 90 days of tubal occlusion. However, after reversal, fertility steadily increased to normalcy in groups III (50% at 45 days, 80% at 105 days, 100% at 150 and 195 days) and IV (70% at 45 and 105 days, 100% at 150 and 195 days) animals. Group II illustrated disorganized inner cell linings and eosinated RISUG® implant-filled lumen. Reversal groups (III and IV) revealed complete restoration of cellular histo-architecture. Regular estrous cycle was noticed in all experimental groups. Conclusion: RISUG® is suitable for single intervention, intratubular, reversible contraception in female rats. Key words: Contraception, Fallopian tube, Tubal occlusion, RISUG®, Reversible.